乌帕替尼与阿达木单抗对类风湿关节炎和银屑病关节炎疼痛的影响
该研究为SELECT-COMPARE和SELECT-PsA 1两项3期双盲试验的事后分析,评估乌帕替尼或阿达木单抗对比安慰剂对活动性RA和PsA患者疼痛的影响。结果显示,在炎症减轻的患者中,乌帕替尼对疼痛的改善优于阿达木单抗和安慰剂(RA第12周),且RA中乌帕替尼的直接镇痛效应约为安慰剂的两倍。
要点
- RA炎症减轻患者第12周PtGA疼痛改善:乌帕替尼-42.9优于阿达木单抗-34.7和安慰剂-33.1(p<0.05)。
- PsA炎症减轻患者第12/24周疼痛改善:乌帕替尼优于安慰剂,与阿达木单抗相似。
- RA中乌帕替尼对疼痛的直接效应约为安慰剂的两倍,提示直接镇痛作用。
核心结论
- 乌帕替尼可有效减轻活动性RA和PsA患者的疼痛,包括炎症减轻的患者。
- RA中乌帕替尼较阿达木单抗疼痛缓解更显著,可能同时具有直接和间接效应。
研究设计与样本
- SELECT-COMPARE和SELECT-PsA 1两项3期双盲研究的事后分析。
- 纳入活动性疾病且既往治疗反应不佳的RA和PsA患者。
- 比较乌帕替尼、阿达木单抗与安慰剂对疼痛的影响,并做中介分析。
主要发现
- RA炎症减轻患者第12周PtGA变化:乌帕替尼-42.9,阿达木单抗-34.7(p<0.05),安慰剂-33.1(p<0.05)。
- PsA炎症减轻患者第12周PtGA变化:乌帕替尼-2.7优于安慰剂-1.8(p<0.05);第24周-3.8优于安慰剂-2.8(p<0.001)。
- RA中乌帕替尼对疼痛的直接效应在12/26周约为安慰剂的两倍。
- PsA中第16/24周TJC28改善的总效应:乌帕替尼2.16和2.30,阿达木单抗1.35和1.71,均优于安慰剂。
临床怎么用
- 对于活动性RA和PsA患者,乌帕替尼可考虑用于减轻疼痛,尤其炎症减轻后仍有疼痛者。
- RA患者中乌帕替尼可能较阿达木单抗提供更强的直接镇痛效果。
局限性
- 为事后分析,结果需前瞻性研究验证。
- 疼痛评估基于PtGA和TJC28等间接指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with rheumatoid (RA) or psoriatic (PsA) arthritis can experience debilitating pain. METHODS: Post hoc analyses of phase 3, double-blind studies in patients with active disease despite treatment (SELECT-COMPARE, SELECT-PsA 1) assessed the effects of upadacitinib or adalimumab versus placebo on pain in patients with attenuation of inflammation (AoI) versus remaining inflammation at weeks 12 and 24/26 (PsA/RA). Further, a mediation analysis assessed the direct/indirect effect of treatment on pain using the Patient's Global Assessment of pain (PtGA) and 28 tender joint count (TJC28) at weeks 2/12/26 in RA, and weeks 16/24 in PsA. RESULTS: In patients with RA+AoI, PtGA scores improved more with upadacitinib (least squares mean change, -42.9) versus adalimumab (-34.7 (p<0.05)) or placebo (-33.1 (p<0.05)) at week 12 from baseline; improvements were similar across groups by week 26. For PsA+AoI, improvement was greater with upadacitinib (week 12, -2.7; week 24, -3.8) versus placebo (-1.8 (p<0.05); -2.8 (p<0.001), respectively) and similar to adalimumab (-2.8, -3.6). For RA, the direct effect on pain was nearly two times greater with upadacitinib versus placebo compared with adalimumab at weeks 12/26. For PsA, total effects on pain (TJC28 improvement) at weeks 16/24 were greater with upadacitinib (2.16 and 2.30) and adalimumab (1.35 and 1.71) versus placebo. CONCLUSIONS: Upadacitinib effectively reduced pain in active RA and PsA, including in patients with AoI. The greater pain relief observed in RA with upadacitinib versus adalimumab might indicate both direct (relieving non-inflammatory pain) and indirect (suppressing inflammation) effects.
引用
- Taylor PC, Kavanaugh A, Bessette L, et al. Effects of upadacitinib or adalimumab on pain in rheumatoid arthritis and psoriatic arthritis: results from randomised phase 3 studies. RMD Open. 2026. PMID: 41506743. doi:10.1136/rmdopen-2025-005867
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。